Novo weight loss drug trial shows improvement in fatty liver disease
Novo Nordisk said Friday that its weight-loss drug achieved the primary goal of a late-stage study in patients with fatty liver disease, reducing scarring of the organ without worsening the condition.
POPULAR POSTS
State financing of nature protection measures at COP-16
November 5, 2024
Spain deploys 7,500 troops to flood zone
November 5, 2024
Indonesia is expected to have a normal rainy season in 2025
November 5, 2024
LIVE STREAM